XML 102 R125.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Revenue by product                      
Product, net $ 1,607,100 [1],[2] $ 1,453,600 $ 1,385,900 [3] $ 1,095,800 [4] $ 1,074,700 [5] $ 1,039,100 $ 1,076,800 [6] $ 975,400 $ 5,542,331 $ 4,166,074 $ 3,836,117
U.S
                      
Revenue by product                      
Product, net                 3,581,000 2,176,800 1,954,800
Rest of world
                      
Revenue by product                      
Product, net                 1,961,300 1,989,300 1,881,300
AVONEX
                      
Revenue by product                      
Product, net                 3,005,500 2,913,100 2,686,600
AVONEX | U.S
                      
Revenue by product                      
Product, net                 1,902,400 1,793,700 1,628,300
AVONEX | Rest of world
                      
Revenue by product                      
Product, net                 1,103,100 1,119,400 1,058,300
TYSABRI
                      
Revenue by product                      
Product, net                 1,526,500 1,135,900 1,079,500
TYSABRI | U.S
                      
Revenue by product                      
Product, net                 814,200 383,100 326,500
TYSABRI | Rest of world
                      
Revenue by product                      
Product, net                 712,300 752,800 753,000
TECFIDERA
                      
Revenue by product                      
Product, net                 876,100 0 0
TECFIDERA | U.S
                      
Revenue by product                      
Product, net                 864,400 0 0
TECFIDERA | Rest of world
                      
Revenue by product                      
Product, net                 11,700 0 0
Other products
                      
Revenue by product                      
Product, net                 134,200 117,100 70,000
Other products | U.S
                      
Revenue by product                      
Product, net                 0 0 0
Other products | Rest of world
                      
Revenue by product                      
Product, net                 $ 134,200 $ 117,100 $ 70,000
[1] Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[2] Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[3] Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[4] Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
[5] Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
[6] Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.